
|Articles|September 20, 2012
Yervoy footer
Advertisement
© 2012 Bristol-Myers Squibb Company, Princeton, NJ 08543 U.S.A.
731US12WA22001 10/12
Advertisement
Related Content
Advertisement



77 Updated Efficacy of Mutant-Selective PI3Kα Inhibitor Zovegalisib (RLY-2608) in Combination With Fulvestrant in Patients With PIK3CA-Mutant HR+/HER2– Advanced Breast Cancer: ReDiscover Trial
BySarah L. Sammons,Cristina Saura,Antoine Italiano,Alison Schram, MD,Pablo Tolosa,Anne F. Schott, MD,Á. Guerrero-Zotano,Santiago Ponce-Aix,Rita Nanda, MD,Kari B. Wisinski, MD,Jennifer Segar,Mei Wei,Jia (Jenny) Liu,Alexander Spira, MD, PhD, FACP, FASCO,Julia E. McGuinness, MD,Jordi Rodón,Cynthia X. Ma, MD, PhD,Milana Bergamino,Giuseppe Curigliano,Andreas Varkaris


Advertisement
Advertisement
Trending on CancerNetwork
1
Melanoma Trials You May Have Missed at ASCO 2026
2
Daraxonrasib/Vopimetostat Yield Stunning Response Rate in MTAP-del Pancreatic Cancer
3
NMPA Grants ADRX-0405 IND Clearance in Late-Stage Solid/Prostate Tumors
4
Radiation Oncology Trials You May Have Missed at ASCO 2026
5

































































